

**This item is the archived peer-reviewed author-version of:**

Novel microdeletions on chromosome 14q32.2 suggest a potential role for non-coding RNAs in Kagami-Ogata syndrome

**Reference:**

van der Werf Ilse, Buiting Karin, Czeschik Christina, Reyniers Edwin, Vandeweyer Geert, Vanhaesebrouck Piet, Lüdecke Hermann-Josef, Wieczorek Dagmar, Horsthemke Bernhard, Mortier Geert, ....- Novel microdeletions on chromosome 14q32.2 suggest a potential role for non-coding RNAs in Kagami-Ogata syndrome  
European journal of human genetics / European Society of Human Genetics - ISSN 1018-4813 - 24(2016), p. 1-6  
Full text (Publisher's DOI): <http://dx.doi.org/doi:10.1038/EJHG.2016.82>  
To cite this reference: <http://hdl.handle.net/10067/1364380151162165141>

1 **Novel microdeletions on chromosome 14q32.2 suggest a potential role for non-**  
2 **coding RNAs in Kagami-Ogata syndrome**

3 Running title: Novel microdeletions in Kagami-Ogata syndrome

4 Ilse M. van der Werf<sup>1</sup>, Karin Buiting<sup>2</sup>, Christina Czeschik<sup>2</sup>, Edwin Reyniers<sup>1</sup>, Geert  
5 Vandeweyer<sup>1</sup>, Piet Vanhaesebrouck<sup>3</sup>, Hermann-Josef Lüdecke<sup>2</sup>, Dagmar Wiczorek<sup>2,4</sup>,  
6 Bernhard Horsthemke<sup>2</sup>, Geert Mortier<sup>1</sup>, Jules G. Leroy<sup>5</sup>, R. Frank Kooy<sup>1</sup>

7

8 1. Department of Medical Genetics, University and University Hospital Antwerp,  
9 Antwerp, Belgium

10 2. Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen,  
11 Essen, Germany

12 3. Department of Neonatology, Ghent University Hospital, Ghent, Belgium

13 4. Institut für Humangenetik, Universitätsklinikum Düsseldorf, Heinrich-Heine-  
14 Universität, Düsseldorf, Germany

15 5. Greenwood Genetic Center, Greenwood, South Carolina, USA

16

17 Corresponding author:

18 Dr. R. Frank Kooy

19 Department of Medical Genetics, University of Antwerp

20 Prins Boudewijnlaan 43

21 2650 Edegem, Belgium

22 tel. +32 (0)3 275 97 60

23 fax: +32 (0)3 275 97 22

24 E-mail: Frank.Kooy@uantwerpen.be

25

26 **Conflict of interest statement:**

27 The authors declare no conflict of interest.

28 **Abstract**

29 In approximately 20% of individuals with Kagami-Ogata syndrome (KOS14, MIM  
30 608149), characterized by a bell-shaped thorax with coat-hanger configuration of the  
31 ribs, joint contractures, abdominal wall defects and polyhydramnios during the  
32 pregnancy, the syndrome is caused by a maternal deletion of the imprinted gene cluster  
33 in chromosome 14q32.2. Most deletions reported so far included one or both of the  
34 differentially methylated regions *DLK1/MEG3* IG-DMR and *MEG3*-DMR. We present  
35 two unrelated families with two affected siblings each, presenting with classical KOS14  
36 due to maternally inherited microdeletions. Interestingly, all four patients have lived  
37 through to adulthood, even though mortality rates for patients with KOS14 due to a  
38 microdeletion are relatively high. In the first family, none of the differentially  
39 methylated regions (DMRs) is included in the deletion and the methylation status is  
40 identical to controls. Deletions that do not encompass the DMRs in this region are thus  
41 sufficient to elicit the full KOS14 phenotype. In the second family, a partially  
42 overlapping deletion including both DMRs and *MEG3* was detected. In summary, we  
43 show that patients with KOS14 can live into adulthood, that causal deletions do not  
44 have to include the DMRs and that consequently a normal methylation pattern does not  
45 exclude KOS14.

46

47 **Keywords**

48 Imprinting – Kagami-Ogata syndrome – microdeletions – 14q32.2

49

50

51 **Introduction**

52           The human chromosome region 14q32 contains a number of imprinted genes  
53 that are either expressed from the paternal (e.g. *DLK1* and *RTL1*) or from the maternal  
54 allele (e.g. *MEG3*, *RTL1as* and *MEG8*). The locus contains two differentially  
55 methylated regions (DMRs ) involved in imprinting regulation which are unmethylated  
56 on the maternal allele. The germline-derived *DLK1-MEG3* intergenic DMR (IG-DMR)  
57 is located between the *DLK1* and *MEG3* gene and operates as an imprinting control  
58 center in the placenta, whereas the postfertilization-derived *MEG3*-DMR resides in the  
59 promoter region of the *MEG3* gene and functions as an imprinting control center in the  
60 embryo <sup>1-3</sup>. The IG-DMR regulates the methylation status of the *MEG3*-DMR <sup>4,5</sup>. A  
61 maternal deletion of the IG-DMR therefore affects the methylation status of the *MEG3*-  
62 DMR, while a maternal deletion of the *MEG3*-DMR does not affect the methylation  
63 status of the IG-DMR.

64           Paternal uniparental disomy of chromosome 14, or UPD(14)pat, involving the  
65 imprinted region on 14q32.2 is known as Kagami-Ogata syndrome (KOS14, MIM  
66 #608149). Patients are characterized by a small bell-shaped thorax with a coat-hanger  
67 configuration of the ribs, abdominal wall defects, joint contractures and polyhydramnios  
68 during the pregnancy <sup>6,7</sup>. The reciprocal disorder (UPD(14)mat, nowadays known as  
69 Temple syndrome (TS14, MIM #616222)) is characterized by short stature,  
70 developmental delay and early puberty <sup>6</sup>. KOS14 is caused by UPD(14)pat in  
71 approximately 65% of cases, by maternal microdeletions in the *DLK1/MEG3* region in  
72 19% of cases and by hypermethylation of the differentially methylated regions in 15%  
73 of patients <sup>8</sup>. It has been suggested that an excessive *RTL1* expression caused by  
74 absence of the antisense transcript *RTL1as* and absent *MEG* expression underlie many

75 of the phenotypic consequences of the KOS14, but the precise genotype-phenotype  
76 correlation has not been fully elucidated as yet<sup>9</sup>.

77 Here, we present two families, both with two affected sibs, with a maternal  
78 microdeletion on chromosome 14q32.2. The first family carries a deletion that does not  
79 include any of the two DMRs and without methylation abnormalities. The second  
80 family carries a deletion that contains both DMRs and part of the *MEG3* gene, but not  
81 the *RTL1as* gene.

82

### 83 **Materials and Methods**

84

#### 85 *Subjects*

86 Two families (Family A and Family B), both with two affected siblings, were referred  
87 for microarray analysis to search for a cause of their disease. All patients displayed the  
88 clinical features of Kagami-Ogata syndrome during childhood, which was not yet  
89 described in literature at that time and thus not diagnosed. Extensive clinical  
90 descriptions of all patients, including pedigrees, clinical pictures and radiographical  
91 thorax images are available in the Supplementary Information.

92

#### 93 *Microarray*

94 DNA was extracted from peripheral blood using standard methods. SNP array analysis  
95 in patients AII.1 and AII.2 was performed using a HumanCytoSNP-12 v2.1 beadchip on  
96 an iScan system, following standard protocols as provided by the manufacturer  
97 (Illumina, San Diego, California, USA). CNV analysis was performed using CNV-  
98 Webstore.<sup>10</sup> Familial relationships were validated based on the SNP pattern inheritance.

99 In patients BII.1 and BII.3, array analysis was performed using the Affymetrix Genome-  
100 Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA). The data of all  
101 patients are deposited in the Decipher database with submission IDs 326793 (AII.1),  
102 326787 (A.II.2), 327656 (BII.1) and 327657 (BII.3)  
103 (<https://decipher.sanger.ac.uk/index>).

#### 104 *Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)*

105 Gene dosage of the imprinted DLK1/MEG3 locus and methylation of the MEG3  
106 promoter region on chromosome 14q32 were analyzed by MS-MLPA using the SALSA  
107 MLPA KIT ME032-A1 kit (MRC Holland, Amsterdam, Netherlands). Hybridization,  
108 ligation and PCR reactions were performed according to the manufacturer's  
109 instructions. Amplification products were analyzed by capillary electrophoresis using  
110 the ABI3100 capillar sequencer. Data analysis was carried out using the Gene Marker  
111 Software (Softgenetics, State College, PA, USA).

112

#### 113 *DNA methylation analysis of the DLK1-MEG3 IG-DMR by next generation bisulfite* 114 *sequencing*

115 Bisulfite treatment was performed using the EZ DNA Methylation-Gold Kit (Zymo  
116 Research Europe, Freiberg, Germany) according to the manufacturer's instructions. For  
117 each individual, bisulfite amplicon libraries were generated and sample-specific barcode  
118 sequences were added. The amplicons were purified, diluted and clonally amplified in  
119 an emulsion PCR before sequencing on the Roche/454 GS junior system (Branford, CT,  
120 USA). A detailed description has been published previously.<sup>5,11</sup> For subsequent data  
121 analysis the Amplifyzer software was used  
122 (<https://bitbucket.org/svenrahmann/amplifyzer/downloads>). A minimum of 1200 reads

123 for each sample was obtained. Only reads with a conversion rate over 95% were  
124 considered.

125

#### 126 *Copy number profiling using qPCR*

127 Copy number profiling using quantitative PCR was done as described by D'haene *et*  
128 *al.*<sup>12</sup>. In short, several primer pairs were designed to amplify 80-150 basepairs each.  
129 Quantitative PCR on patient DNA samples was performed using the qPCR Mastermix  
130 Plus for SYBR Green I – no ROX (Eurogentec, Liège, Belgium) according to the  
131 manufacturer's protocol, on a Lightcycler480 (Roche, Basel, Switzerland). Data  
132 analysis was performed using qbase+ (Biogazelle, Ghent, Belgium).

133

#### 134 *Targeted Locus Amplification sequencing (TLA-sequencing)*

135 Viably frozen cells from an EBV-cell line of patient AII.1 were sent to Cergentis B.V.  
136 (Utrecht, the Netherlands) for TLA-sequencing. Sample preparation, sequencing and  
137 data-analysis were performed as described in de Vree *et al.*<sup>13</sup>

138

#### 139 *Sanger sequencing*

140 Primers were designed using Primer3Plus.<sup>14</sup> PCR was performed with the GoTaq G2  
141 Polymerase kit (Promega Benelux, Leiden, the Netherlands) according to the guidelines  
142 of the manufacturer. PCR clean-up was performed using alkaline phosphatase (Roche,  
143 Basel, Switzerland) and exonuclease I (Bioké, Leiden, the Netherlands). Sanger  
144 sequencing reactions were done using the ABI PRISM BigDye Terminator Cycle  
145 Sequencing Ready Reaction Kit with readout on an ABI3130XL sequencer (Applied

146 Biosystems Inc., Foster City, CA, USA). CLC DNA Workbench 5.0.2 (CLC bio,  
147 Aarhus, Denmark) was used for data-analysis.

148



149 **Results**

150 The phenotypes of the patients in family A (AII.1 and AII.2) strongly suggested a  
151 diagnosis of UPD(14)pat when first evaluated in the clinic in the early 1990s.  
152 Karyotypes were performed to search for a Robertsonian translocation, but no  
153 abnormalities were detected. Microsatellite analysis, the most sensitive detection  
154 method at that time, did not detect any evidence for UPD. Further genetic testing was  
155 not performed until recently, when SNP array analysis became available and revealed a  
156 microdeletion in both siblings on chromosome 14q32.2 within the imprinted domain of  
157 this chromosomal region hg19  
158 chr14:g.(101290183\_101297515)\_(101361403\_101367310)del. Microarray analysis of  
159 the mother (AI.2) was suggestive for the presence of this microdeletion in a mosaic state  
160 (Supplementary Information). To further delineate the critical region for the KOS14  
161 phenotype in this family, we performed copy number profiling using quantitative  
162 polymerase chain reactions (qPCR). Using these qPCR assays, we refined the  
163 breakpoints to a region of minimally 65.8 kb and maximally 66.5 kb. Copy number  
164 qPCR confirmed the presence of the exact same deletion in the mother in mosaic state.  
165 Attempts to span the breakpoint by PCR assays failed to produce an amplicon,  
166 suggesting the presence of a more complex rearrangement. Targeted Locus  
167 Amplification (TLA)-sequencing was performed in patient AII.1 and revealed that the  
168 deletion contained a 16 kb insertion, including a part of the *EIF5* gene derived from a  
169 downstream chromosomal region. Copy number qPCR assays specifically targeting this  
170 sequence showed that three copies of the insertion were present in patients AII.1 and  
171 AII.2 and confirmed the mosaic state in the mother. A schematic overview of the  
172 rearrangement, depicting that the duplicated sequence was inserted in reverse

173 orientation is shown in figure 1. Sanger sequencing of the fusion points confirmed the  
174 exact rearrangement in patient AII.1 and showed that the same rearrangement is present  
175 in patient AII.2 and the mother of these siblings (hg19  
176 chr14:g.(101297067)\_(101362959)del, hg19  
177 chr14:g.(103809080)\_(103825690)inv\_ins). The deletion affects three maternally  
178 expressed genes: all exons except for the first three of the maternally expressed gene 3  
179 (*MEG3*), the entire *RTL1as* gene and the upstream region and first exon of *MEG8*. None  
180 of the two differentially methylated regions (DMRs) that reside upstream of the *MEG3*  
181 gene (IG-DMR and *MEG3*-DMR) were involved in the deleted region. Methylation  
182 analysis by MS-MLPA and next generation bisulfite sequencing revealed a normal  
183 methylation pattern at the *MEG3*-DMR and the IG-DMR loci (Figure 2, Supplementary  
184 Information).

185 Although patients BII.1 and BII.3 presented with typical clinical findings of Kagami-  
186 Ogata syndrome, the syndrome was not yet described in literature at the time they were  
187 born. Thus, a diagnosis was not established until their healthy brother came to the clinic  
188 asking for genetic counseling because of two affected sibs with ID. Conventional  
189 chromosome analysis in the family showed no signs of a chromosomal rearrangement.  
190 However, SNP array analysis identified a 130 kb microdeletion in 14q32 hg19  
191 chr14:g.(101204495\_101209293)\_(101340188\_101340732)del in patient BII.1. The  
192 deletion includes *MEG3* as well as both imprinting control regions *MEG3*-DMR and  
193 IG-DMR. Presence of the deletion in patient BII.1 was confirmed by qPCR and MLPA.  
194 Dosage analysis by qPCR and MLPA in the affected brother (BII.3) showed that he is  
195 also a carrier. The deletion was absent in the unaffected brother and the parents.  
196 Methylation analysis by MS-MLPA of the *MEG3*-DMR showed hypermethylation,

197 consistent with paternal inheritance of the remaining allele and thus indicating that the  
198 deletion is maternally inherited. MS-MLPA revealed the same hypermethylation in the  
199 affected brother (patient BII.3) but normal methylation patterns in the parents (Figure 2,  
200 Supplementary Information). As the mother does not show any evidence for the deletion  
201 in peripheral leukocytes, MS-MLPA was additionally performed on DNA extracted  
202 from epithelium of the oral mucosa, to identify a potential somatic mosaicism. Again,  
203 dosage and methylation analysis did not reveal any evidence of a deletion. It is therefore  
204 plausible that she has a germline mosaicism for this deletion, although a very low-grade  
205 somatic mosaicism not detectable by MS-MLPA cannot be excluded. In line with this  
206 hypothesis, microsatellite analysis of the 14q32 region using six informative markers  
207 (*D14S987*, *D14S979*, *D14S267*, *D14S250*, *D14S1006* and *D14S1010*) showed that both  
208 affected siblings and the healthy brother have inherited the same maternal allele.  
209 However, for the marker *D14S985*, which lies inside the deletion (in intron 3 of *MEG3*),  
210 the healthy brother has inherited both a paternal and maternal allele whereas his affected  
211 sibs lacks a maternal allele due to the deletion.

212

## 213 **Discussion**

214 A detailed description of the clinical features in combination with the molecular  
215 causes of disease is helpful in correlating the genotype with the phenotype and in  
216 elucidating the specific role of the individual transcripts in the 14q32.2 imprinted region  
217 in the emergence of the KOS14 phenotype<sup>15</sup>. Here, we add two pairs of siblings from  
218 two unrelated families with a maternally inherited microdeletion in the 14q32  
219 imprinting region to the cohort of 34 recently reported KOS14 patients<sup>15</sup>. All four  
220 affected individuals survived into adulthood, with relatively mild phenotypes compared

221 to the patients with KOS14 due to a microdeletion that have been described<sup>15</sup>. Mortality  
222 rates of KOS14 appear to be associated with premature birth and mutation type, with  
223 death typically occurring before the age of four. In a cohort of 34 patients described by  
224 *Kagami et al.*<sup>15</sup> the survival rate of deletion carriers was only 50%, while a survival rate  
225 of 78% was observed for the UPD(14)pat group and even 100% for the individuals with  
226 epimutations. Causes of death were variable, but overall respiratory problems seem to  
227 play a major role.

228 Patient AII.1 presented the typical coat-hanger sign of the ribs and the bell-  
229 shaped deformity of the thorax that is characteristic for KOS14. The deformity  
230 diminished during development and to date she is an ambitious young lady, who suffers  
231 from recurrent respiratory infections and easy tiring. Her brother, patient AII.2, not only  
232 showed the typical deformities of the thoracic cage as classical KOS14, but next to that  
233 also presented with abdominal wall defects, distal arthrogyposis deformities and  
234 polyhydramnios during the pregnancy, features commonly observed in KOS14 patients.  
235 To date he suffers from mild intellectual disability (ID) and persistent hypotonia. Even  
236 though patients AII.1 and AII.2 carry the exact same deletion, she is less severely  
237 affected than her younger brother. The ID seen in patient AII.2 is a feature commonly  
238 seen in KOS14 and thus might be intrinsic to the disease, but in his case might also be  
239 the result of unnoticed hypoxic periodes in the neonatal period due to the skeletal  
240 malformations of the thorax. . In contrast, his sister AII.2 finished academic education  
241 and the KOS14 phenotypic features she presented with during early childhood almost  
242 completely normalized. In a previously reported sibling pair carrying a 5.8 kb deletion  
243 affecting the *MEG3*-DMR and the first three exons of the *MEG3* gene the clinical  
244 course of the girl was also in general milder than that of her older brother<sup>5</sup>. Even

245 though this may well be a coincidental observation, gender-determined factors cannot  
246 be ruled-out at the moment.

247 Patient BII.1 was born prematurely and showed a bell-shaped thorax, general  
248 muscular hypotonia, bilateral inguinal hernia and diastasis recti. He displayed mild  
249 developmental delay, but managed to complete vocational training and works as an  
250 office clerk to date. His younger brother, patient BII.3, also showed the bell-shaped  
251 deformity of the thorax, combined with respiratory distress, bilateral inguinal hernia and  
252 general muscular hypotonia. He completed special education and currently works in a  
253 sheltered workshop. The patients we present here, all display (mild) clinical features due  
254 to the maternally inherited deletion on chromosome 14, but live through adulthood  
255 which is remarkable for patients with Kagami-Ogata syndrome caused by a  
256 microdeletions. All of the patients, except patient AII.2 were able to finish education to  
257 some extent and obtain a job that is consistent with their respective education levels.  
258 Overall, a reduction in the thoracic abnormalities was observed during the development,  
259 suggesting that these are deformations rather than malformations. These skeletal  
260 malformations might be attributed to reduced bone hardness, through which the  
261 deformation of the skull seen in patient AII.2 could also be explained. As these skeletal  
262 deformations, especially the narrow thorax, can be detected prenatally by ultrasound,  
263 intensive neonatal care should be provided as soon as possible upon birth to prevent  
264 hypoxia-induced damage.

265 To our knowledge, 13 patients with a UPD(14)pat phenotype caused by a  
266 maternal 14q32 deletion have been reported<sup>3-5,16,17</sup>. The precise localization of these is  
267 depicted in figure 3. The clinical characteristics of all deletion carriers, including the  
268 cases described here are summarized in table 1. Kagami *et al.*<sup>3</sup> reported four different

269 deletions in five cases. The phenotype ranged from typical (e.g., cases 1+2) to relatively  
270 mild KOS14 (e.g., cases 3-5). Subsequently, two patients with a severe KOS14  
271 phenotype were described, both carrying a remarkably small deletion that only  
272 encompasses one of the two DMRs<sup>3,4</sup>. Beygo *et al.*<sup>5</sup> described two novel maternal  
273 microdeletions as the cause of the KOS14 phenotype in three additional cases, including  
274 a sibling pair. All initial 10 cases had a deletion which included at least one or both  
275 imprinting control centers (IG-DMR and *MEG3*-DMR). Because of the hierarchical  
276 regulation of these imprinting clusters, in which the IG-DMR influences the  
277 methylation of the *MEG3*-DMR aberrant methylation of the *MEG3*-DMR was likely  
278 present in all. However, the deletion detected in our family A does not include either  
279 one of the DMRs, suggesting that the involvement of the DMRs is not essential for the  
280 development of the disorder. Using MS-MLPA and bisulfite sequencing, abnormal  
281 methylation was ruled out in family A, indicating that the maternally inherited absence  
282 of *MEG3*, *RTL1as* and *MEG8 per se* is causative for the phenotype in this family rather  
283 than aberrant methylation of the DMRs. Interestingly, TLA-sequencing unraveled the  
284 presence of a complex rearrangement, in which a 16 kb sequence, derived from a region  
285 downstream of the deletion, was duplicated and inserted in reverse orientation. The  
286 precise molecular mechanism through which this rearrangement arose is unclear, but it  
287 is concordant with a Fork Stalling and Template Switching (FoSTes) model<sup>18,19</sup>. As the  
288 inserted sequence does not contain the complete *EIF5* gene and two intact copies, one  
289 on each allele of this gene are still present, we consider it unlikely that the *EIF5* gene  
290 contributes to the clinical presentation of KOS14 in our patients.

291           While preparing this manuscript, three additional microdeletions were reported  
292 that did not include the DMRs, like in our family A<sup>16,17</sup>. As visualized in figure 3, there

293 is no smallest region of overlap common to all 13 microdeletions. It is therefore likely  
294 that several regulatory mechanisms can be disrupted at different positions within the  
295 14q32.2 chromosomal region with a similar clinical outcome. It is generally accepted  
296 that aberrant expression of the maternally transcribed copies of *MEG3*, *MEG8* or  
297 *RTL1as* -either through the disruption of the imprinting control centers IG-DMR and  
298 *MEG3*-DMR or through direct disruption of the genes by a deletion- plays a crucial role  
299 in the pathogenesis of KOS14, although an effect of other regulatory sequences cannot  
300 be excluded. Little is known about the function of the long non-coding RNAs *MEG3*  
301 and *MEG8*. Maternal *RTL1as* transcripts function to repress *RTL1* transcripts from the  
302 paternal allele and absence of *RTL1as* has leads to an increase *RTL1* expression <sup>20</sup>.  
303 Increased expression of *RTL1*, potentially combined with the effects of absent  
304 expression of *MEGs* has been hypothesized to play a key role in the pathogenesis of  
305 KOS14 <sup>9</sup>. This hypothesis is strengthened by the observation that the *RTL1as* transcript  
306 is commonly deleted in the microdeletions that do not affect the imprinting control  
307 centers. The deletion in family B contains both imprinting control centers and *MEG3*,  
308 but not the *RTL1as* transcript, neither *MEG8*. However, it is not known whether in our  
309 patients BII.1 and BII.3 the transcription of *RTL1as* and *MEG8* is also affected. In a  
310 mouse model, absence of the first exons of *Gtl2*, the murine homologue of *MEG3*, has  
311 been reported to silence the expression of all maternally expressed genes <sup>21</sup>.

312 In summary, we show that some patients with KOS14 can live into adulthood,  
313 which should have an impact on handling these patients in a neonatal care unit. In  
314 addition we demonstrate that deletions not including the IG-DMR nor the *MEG3*-DMR  
315 and devoid of methylation abnormalities can lead to KOS14, emphasizing the  
316 importance of the non-coding transcripts in the region.

317

318 Supplementary information is available at the European Journal of Human Genetics

319 website



320 **Acknowledgements:**

321 We thank dr. Max van Min for his advice on TLA sequencing, Christina Lich for  
322 technical assistance and Jasmin Beygo for her help with figures and helpful discussions.  
323 IMvdW is funded by the Special Research Fund of the University of Antwerp  
324 [Bijzonder Onderzoeksfonds (BOF-IWT)]. GV is a postdoctoral fellow of the Research  
325 Fund Flanders (FWO). Part of the work was funded by the Bundesministerium für  
326 Bildung und Forschung (Network Imprinting diseases, 01GM1513A).

327

328 **Conflict of interest statement:**

329 The authors declare no conflict of interest.

330

331 **References**

- 332 1 Lin SP, Youngson N, Takada S *et al*: Asymmetric regulation of imprinting on the  
333 maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on mouse  
334 chromosome 12. *Nat Genet* 2003; **35**: 97-102.
- 335 2 Paulsen M, Takada S, Youngson NA *et al*: Comparative sequence analysis of the  
336 imprinted Dlk1-Gtl2 locus in three mammalian species reveals highly conserved  
337 genomic elements and refines comparison with the Igf2-H19 region. *Genome Res*  
338 2001; **11**: 2085-2094.
- 339 3 Kagami M, Sekita Y, Nishimura G *et al*: Deletions and epimutations affecting the  
340 human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-  
341 like phenotypes. *Nat Genet* 2008; **40**: 237-242.
- 342 4 Kagami M, O'Sullivan MJ, Green AJ *et al*: The IG-DMR and the MEG3-DMR at human  
343 chromosome 14q32.2: hierarchical interaction and distinct functional properties as  
344 imprinting control centers. *PLoS Genet* 2010; **6**: e1000992.
- 345 5 Beygo J, Elbracht M, de Groot K *et al*: Novel deletions affecting the MEG3-DMR provide  
346 further evidence for a hierarchical regulation of imprinting in 14q32. *Eur J Hum Genet*  
347 2015; **23**: 180-188.
- 348 6 Sutton VR, Shaffer LG: Search for imprinted regions on chromosome 14: comparison of  
349 maternal and paternal UPD cases with cases of chromosome 14 deletion. *Am J Med*  
350 *Genet* 2000; **93**: 381-387.
- 351 7 Kagami M, Nishimura G, Okuyama T *et al*: Segmental and full paternal isodisomy for  
352 chromosome 14 in three patients: narrowing the critical region and implication for the  
353 clinical features. *Am J Med Genet A* 2005; **138A**: 127-132.
- 354 8 Kagami M, Kato F, Matsubara K, Sato T, Nishimura G, Ogata T: Relative frequency of  
355 underlying genetic causes for the development of UPD(14)pat-like phenotype. *Eur J*  
356 *Hum Genet* 2012; **20**: 928-932.
- 357 9 Ogata T, Kagami M: Kagami-Ogata syndrome: a clinically recognizable upd(14)pat and  
358 related disorder affecting the chromosome 14q32.2 imprinted region. *J Hum Genet*  
359 2015.
- 360 10 Vandeweyer G, Reyniers E, Wuyts W, Rooms L, Kooy RF: CNV-WebStore: Online CNV  
361 Analysis, Storage and Interpretation. *BMC Bioinformatics* 2011; **12**: 4.
- 362 11 Beygo J, Citro V, Sparago A *et al*: The molecular function and clinical phenotype of  
363 partial deletions of the IGF2/H19 imprinting control region depends on the spatial  
364 arrangement of the remaining CTCF-binding sites. *Human Molecular Genetics* 2013;  
365 **22**: 544-557.
- 366 12 D'Haene B, Vandesompele J, Hellemans J: Accurate and objective copy number  
367 profiling using real-time quantitative PCR. *Methods* 2010; **50**: 262-270.
- 368 13 de Vree PJ, de Wit E, Yilmaz M *et al*: Targeted sequencing by proximity ligation for  
369 comprehensive variant detection and local haplotyping. *Nat Biotechnol* 2014; **32**:  
370 1019-1025.
- 371 14 Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA: Primer3Plus, an  
372 enhanced web interface to Primer3. *Nucleic Acids Res* 2007; **35**: W71-74.
- 373 15 Kagami M, Kurosawa K, Miyazaki O, Ishino F, Matsuoka K, Ogata T: Comprehensive  
374 clinical studies in 34 patients with molecularly defined UPD(14)pat and related  
375 conditions (Kagami-Ogata syndrome). *Eur J Hum Genet* 2015; **23**: 1488-1498.
- 376 16 Corsello G, Salzano E, Vecchio D *et al*: Paternal uniparental disomy chromosome 14-  
377 like syndrome due a maternal de novo 160 kb deletion at the 14q32.2 region not

378 encompassing the IG- and the MEG3-DMRs: Patient report and genotype-phenotype  
379 correlation. *Am J Med Genet A* 2015.

380 17 Rosenfeld JA, Fox JE, Descartes M *et al*: Clinical features associated with copy number  
381 variations of the 14q32 imprinted gene cluster. *Am J Med Genet A* 2015; **167A**: 345-  
382 353.

383 18 Lee JA, Carvalho CMB, Lupski JR: A DNA replication mechanism for generating  
384 nonrecurrent rearrangements associated with genomic disorders. *Cell* 2007; **131**:  
385 1235-1247.

386 19 Liu P, Carvalho CM, Hastings P, Lupski JR: Mechanisms for recurrent and complex  
387 human genomic rearrangements. *Curr Opin Genet Dev* 2012.

388 20 Kagami M, Matsuoka K, Nagai T *et al*: Paternal uniparental disomy 14 and related  
389 disorders: placental gene expression analyses and histological examinations.  
390 *Epigenetics* 2012; **7**: 1142-1150.

391 21 Benetatos L, Hatzimichael E, Londin E *et al*: The microRNAs within the DLK1-DIO3  
392 genomic region: involvement in disease pathogenesis. *Cell Mol Life Sci* 2013; **70**: 795-  
393 814.

394

395

396 **Titles and legends to figures**

397

398 **Figure 1: Schematic representation of the causal structural rearrangement in**

399 **Family A.**

400 Upper scheme represents the normal state, lower scheme represents the rearranged state  
401 of the 14q region in the patients. The genes involved in the rearrangement are  
402 represented by the blue boxes, grey boxes indicate a differentially methylated region  
403 (DMR). Arrowheads indicate the 5' to 3' direction. The green section is deleted in the  
404 patients, the red section is duplicated and inserted in between the deletion breakpoints in  
405 reverse orientation.


406

407 **Figure 2: Comparative methylation heatmap obtained by next generation bisulfite**  
408 **sequencing of *MEG3* and the *DLKI/MEG3* IG-DMR.**


409 Patient BII.1 and BII.3 showed hypermethylation due to the deletion of the  
410 unmethylated maternal allele at both loci, whereas patients AII.1 and AII.2 and their  
411 mother showed normal methylation values around 50%. Patient AII.1 showed  
412 hypomethylation at CpG2 of the IG-DMR because she is heterozygous or homozygous  
413 for a C to T exchange (rs1458662425:C>T (hg19. chr14:g.101277356C>T)) on the  
414 methylated paternal allele. Each square represents a CpG dinucleotide with its average  
415 methylation level, each line a specific sample. The average methylation over the  
416 analyzed region is given in percentage under the individual sample together with the  
417 number of analyzed reads in brackets. The methylation was analyzed over eleven CpGs  
418 at the *MEG3*-DMR and three CpGs at the *DLKI/MEG3* IG-DMR. P indicates patient.

419


420 **Figure 3: Reported microdeletions in 14q32.2 leading to the KOS14 phenotype.**  
421 Horizontal bars represent all cases known to date carrying a microdeletion on their  
422 maternal allele, the length of the bars indicates the size and genes encompassed by the  
423 respective deletions. Grey shaded boxes reflect the position of differentially methylated  
424 regions (DMRs).




Comparative Analysis: MEG3  
5 samples, 11 CpGs



Comparative Analysis: IGDMR  
5 samples, 3 CpGs







**Table 1: Clinical characteristics of patients with Kagami-Ogata Syndrome caused by a mat**

	Kagami et al. 2008	Kagami et al. 2010
Number of patients	5	2
Gender (Female:Male)	3:2	2:0

**Molecular findings**

IG-DMR of maternal origin	deleted (5/5)	deleted (1/2)
MEG3-DMR of maternal origin	deleted (5/5)	deleted (1/2)

**Prenatal**

Polyhydramnios	+ (4/5)	+ (1/2)
Other		

**Neonatal**

Gestational age in weeks (range)	27-35	28-33
Hypotonia	?	?
Feeding difficulties	?	?

**Thorax**

Bell-shaped thorax with coat-hanger ribs	+ (5/5)	+ (2/2)
Mechanical ventilation	+ (5/5)	+ (2/2)
Other		

**Abdomen**

Diastasis recti	+ (2/5)	?
Omphalocele	-	+ (2/2)
Other		bilateral hydronephrosis (1/2)

**Extremities**

Joint contractures	+ (2/5)	+ (1/2)
Hyperextensibility of small joints	?	?

**Development**

Education	?	?
Developmental delay	+ (3/5)	?

+ Feature is present

- Feature is absent

? Feature is not described as present or absent

teral microdeletion in chr14q32.2

Beygo et al. 2014	Corsello et al. 2015	Rosenfeld et al. 2015	All.1
3	1	2	
1:2	Female	2:0	Female

unaffected	unaffected	unaffected	unaffected
deleted (3/3)	unaffected	unaffected	unaffected

+ (3/3)	+	+ (2/2)	?

32-35	35	?	41
+ (3/3)	?	+ (1/2)	+
+ (2/3)	+	?	-

+ (3/3)	+	+ (2/2)	+
+ (3/3)	+	?	-

+ (1/3)	+	-	
?	-	-	
umbilical hernia (1/3), inguinal hernia (1/3)			

?	+	-	-
-	?	?	+

?	?	?	++
+ (2/3)	?	?	-

		Current study	
AII.2		BII.1	
Male		Male	
unaffected		deleted	
unaffected		deleted	
+		+	
ultrasound finding of bell-shaped, narrow thoracic deformity		premature labour from week 28 onwards	
35		32	
+		+	
+		-	
+		+	
+		-	
		Pectus excavatum	
		+	
		-	
		Bilateral inguinal hernia	
+		-	
-		+/-	
+		+/-	

BII.3
Male

deleted
deleted

+
sonographically suspected encephalocele (not confirmed postnatally)

35
+
+

+
+
Pectus excavatum

-
-
Bilateral inguinal hernia and umbilical hernia

-

+/-
+